Venus Medicine Research Center, Hill Top, Industrial Estate, Jharmajri EPIP, Phase I (Extn) Bhatoli Kalan, Baddi, India.
Folia Microbiol (Praha). 2009 Sep;54(5):391-4. doi: 10.1007/s12223-009-0054-1. Epub 2009 Nov 24.
The efficacy of the agents was evaluated on the basis of minimum inhibitory concentration (MIC) and time-kill curve analysis in Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii, Mycobacterium smegmatis, and Citrobacter braakii; MIC was found to be 0.5, 4.0, 0.015625, 0.0078125, and 0.0625 mg/L in FDC of ceftazidime + sulbactam, respectively, which is lower than ceftazidime and sulbactam individually. Time-kill curve analysis demonstrated maximum killing of bacteria after 4 h. A fixed dose combination of ceftazidime + sulbactam was found to have stronger antibacterial properties than ceftazidime and sulbactam alone at in vitro analysis.
头孢他啶-舒巴坦固定剂量复方制剂的体外药效学研究
在铜绿假单胞菌、金黄色葡萄球菌、鲍曼不动杆菌、耻垢分枝杆菌和产酸克雷伯菌中，根据最低抑菌浓度（MIC）和时间杀菌曲线分析评估了这些药物的疗效；头孢他啶-舒巴坦固定剂量复方制剂的 MIC 值分别为 0.5、4.0、0.015625、0.0078125 和 0.0625 mg/L，低于头孢他啶和舒巴坦单独使用时的 MIC 值。时间杀菌曲线分析表明，4 小时后细菌最大杀灭。体外分析表明，头孢他啶-舒巴坦固定剂量复方制剂的抗菌性能强于头孢他啶和舒巴坦单独使用。
